Compare · NVS vs SHPH
NVS vs SHPH
Side-by-side comparison of Novartis AG (NVS) and Shuttle Pharmaceuticals Holdings Inc. (SHPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and SHPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.27B, about 86389.2x SHPH ($3.5M).
- Over the past year, NVS is up 25.3% and SHPH is down 89.5% - NVS leads by 114.8 points.
- SHPH has hit the wire 5 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 0 for SHPH).
- Company
- Novartis AG
- Shuttle Pharmaceuticals Holdings Inc.
- Price
- $158.74-0.79%
- $3.56+1.14%
- Market cap
- $305.27B
- $3.5M
- 1M return
- -0.66%
- +30.16%
- 1Y return
- +25.29%
- -89.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 0
- 5
- Recent ratings
- 25
- 0
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
Latest SHPH
- SEC Form NT 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Amendment: Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form DEF 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form PRE 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- Large owner Hrt Financial Lp sold $372,704 worth of shares (83,149 units at $4.48), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $30,212 worth of shares (8,997 units at $3.36), increasing direct ownership by 17% to 61,271 units (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 60,540 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $100,461 worth of shares (29,111 units at $3.45), decreasing direct ownership by 36% to 52,274 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $27,793 worth of shares (7,851 units at $3.54) and sold $31,667 worth of shares (9,022 units at $3.51), decreasing direct ownership by 1% to 81,385 units (SEC Form 4)